The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

European Heart Journal

Volumn 36, Issue 1, 2015, Pages 51-59

  Miranda, Melroy X ^a   Van Tits, Lambertus J ^a   Lohmann, Christine ^a   Arsiwala, Tasneem ^a   Winnik, Stephan ^a   Tailleux, Anne ^b   Stein, Sokrates ^a,c   Gomes, Ana P ^d   Suri, Vipin ^e   Ellis, James L ^e   Lutz, Thomas A ^a   Hottiger, Michael O ^a   Sinclair, David A ^d   Auwerx, Johan ^c   Schoonjans, Kristina ^c   Staels, Bart ^b   Lüscher, Thomas F ^a   Matter, Christian M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b INSTITUT PASTEUR DE LILLE   (France)

^c EPFL   (Switzerland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Atherogenesis; LDL receptor; LDL cholesterol; Pcsk9; Sirt1

Indexed keywords

AGENTS AFFECTING METABOLISM; APOLIPOPROTEIN E; CARDIOVASCULAR AGENT; ENZYME ACTIVATOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SIRTUIN 1; SRT 3025; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; ANILIDE; ENZYME INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MESSENGER RNA; PCSK9 PROTEIN, MOUSE; SRT3025; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; DEACETYLATION; GENE DELETION; HEART PROTECTION; HEPATOMA CELL; IN VITRO STUDY; INFLAMMATION; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; ANIMAL; ARTERIOSCLEROSIS; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; METABOLISM; SECRETION (PROCESS);

ANILIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELLS, CULTURED; CHOLESTEROL, LDL; ENZYME INHIBITORS; HEPATOCYTES; IN VITRO TECHNIQUES; MALE; MICE, INBRED C57BL; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SIRTUIN 1; THIAZOLES;

EID: 84961291948     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu095     Document Type: Article

References (25)

1. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
2. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008; 80: 191-199.
3. Stein S, Lohmann C, Schafer N, Hofmann J, Rohrer L, Besler C, Rothgiesser KM, Becher B, Hottiger MO, Boren J, McBurney MW, Landmesser U, Luscher TF, Matter CM. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010; 31: 2301-2309.
4. Gorenne I, Kumar S, Gray K, Figg N, Yu H, Mercer J, Bennett M. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013; 127: 386-396.
5. Qiang L, Lin HV, Kim-Muller JY, Welch CL, Gu W, Accili D. Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation. Cell Metab 2011; 14: 758-767.
6. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-1217.
7. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338.
8. Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP, Jacobson E, Wilkins MR, Matthews PM. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012; 7: e51395.
9. Venkatasubramanian S, Noh RM, Daga S, Langrish JP, Joshi NV, Mills NL, Hoffmann E, Jacobson EW, Vlasuk GP, Waterhouse BR, Lang NN, Newby DE. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc 2013; 2: e000042.
10. Dietschy JM, Spady DK. Regulation of low density lipoprotein uptake and degradation in different animals species. Agents Actions Suppl 1984; 16: 177-190.
11. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest 1995; 95: 1124-1132.
12. Sudhof TC, Russell DW, Brown MS, Goldstein JL. 42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter. Cell 1987; 48: 1061-1069.
13. Attie AD, Seidah NG. Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab 2005; 1: 290-292.
14. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008; 48: 646-654.
15. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339: 1216-1219.
16. Revollo JR, Grimm AA, Imai S. TheNADbiosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004; 279: 50754-50763.
17. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999; 83: 1330-1333.
18. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
19. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928-933.
20. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfi A. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011; 12: 1300-1305.
21. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the numberofLDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116: 2995-3005.
22. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013; 127: 2403-2413.
23. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51: 2714-2721.
24. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, Daris M, Sheng J, Wang Y, Shen WD, Yeh WC, Emery M, Walker NP, Shan B, Schwarz M, Jackson SM. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009; 106: 9820-9825.
25. Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgrad Med 2012; 124: 43-54.